No abstract

Hemophilia A (HA) represents one of the most common genetic bleeding disorders worldwide and results from a deficiency in factor VIII (FVIII). The mainstay of treatment for HA is repletion of FVIII. Numerous plasma-derived and recombinant factor concentrates are available, each with clinical advantages and disadvantages. Nonfactor products including desmopressin and antifibrinolytic agents can also be used, depending on the clinical situation and severity of FVIII deficiency. Turoctocog alfa is the most recent addition to recombinant FVIII concentrates available for the treatment of HA. Pharmacokinetic trials in animals and humans have demonstrated characteristics similar to those of other recombinant FVIII concentrates. Clinical trials have supported efficacy and safety in the management of HA in treatment-experienced patients; study results of turoctocog alfa in treatment-naïve patients are pending. A smaller study in hemophilic patients undergoing surgery has demonstrated positive results. Although turoctocog alfa was approved by the U.S. Food and Drug Administration in 2013, it will not be available on the market until 2015. Turoctocog alfa appears to be a safe and effective alternative to currently available recombinant FVIII concentrates; however, its place in therapy among these products has yet to be elucidated.

No abstract

No abstract

No abstract